Outsourced Pharma White Papers

1. Advancing ADCs: From Concept To Commercialization 11/3/2026

   ADC programs move fastest when payload-linker strategy, route design, conjugation, and drug product are planned together, with timelines and scale-up capacity shaping choices from the earliest development stages.

2. Managing Risks With Potent Pharmaceutical Products 11/2/2026

   Manufacturing potent medications safely requires specialized containment, toxicology expertise, and strict contamination controls to ensure compliance, product quality, and worker safety.

3. Is Your API Right For A Soft Gel Capsule? 11/2/2026

   Soft gel delivery systems can enhance bioavailability, enable controlled release, support combination dosing, and handle potent compounds while improving stability and patient adherence.

4. Ensuring Business Continuity In Your Pharmaceutical Commercial Supply 11/2/2026

   Drug shortages demand resilient supply chains and strategic partnerships. Learn how experienced manufacturers help mitigate risks and ensure reliable supply.

5. 10 Qualities Your CDMO Should Have For An Oral Dose Tech Transfer 11/2/2026

   Choose a manufacturing partner that supports every development phase with regulatory expertise, supply chain resilience, and formulation know-how.

6. Biomanufacturing Readiness: A Validation Model For Multiproduct Facilities 10/26/2026

   Optimize your validation strategy to meet evolving regulatory demands and product complexities with a scalable, efficient framework that accelerates facility readiness and ensures consistent quality.

7. Drug Substance Development: Applying Platform Knowledge Across Modalities 10/23/2026

   Upstream processes often transfer readily, while downstream purification and formulation require product-specific adaptation and expert judgment.

8. Manufacturing Oncolytic Viruses: Where Complexity Demands Experience 10/23/2026

   Dose, concentration, potency, purity, recovery, and cost are closely linked in oncolytic virus manufacturing. Learn why early alignment can prevent costly challenges.

9. Integrating Drug Substance And Drug Product To Reduce Risk In Development 10/23/2026

   Discover how integrated planning, shared analytics, and greater continuity can support stronger decisions from early development through commercialization.

10. High-Throughput Binding Affinity Assessment Using Octet® HTX 10/22/2026

    Binding affinity screening of clones directly from crude supernatant, without purification, changes what can be assessed early, and a tiered workflow pairs broad throughput with deeper analytical characterization.